Exhibit 10.46

INTROGEN THERAPEUTICS, INC.

PLACEMENT AGENT AGREEMENT

December 6, 2004

MULIER CAPITAL LIMITED
34 Eccleston Square
London SW1V1NS
London, United Kingdom

Dear Sirs:

     INTROGEN THERAPEUTICS, INC., a Delaware corporation (the “Company”),
proposes to sell to the Investors (defined below), pursuant to the terms of this
Placement Agent Agreement (this “Agreement”) and the Subscription Agreements in
the form of Exhibit A attached hereto (the “Subscription Agreements”) entered
into with the Investors identified therein (each a "Investor” and, collectively,
the “Investors”), an aggregate of up to 4,000,000 shares of Common Stock, $0.001
par value (the “Common Stock”), of the Company. The aggregate of up to 4,000,000
shares so proposed to be sold is hereinafter referred to as the “Stock.” The
Company hereby confirms its agreement with Mulier Capital Limited as the
placement agent for the sale of the Stock to the Investors (the “Placement
Agent”).

1. AGREEMENT TO ACT AS PLACEMENT AGENT; PLACEMENT OF SECURITIES. Subject to all
the terms and conditions of this Agreement:

(a) The Company hereby authorizes the Placement Agent to act as its agent to
solicit from potential purchasers mutually agreed upon by the Placement Agent
and the Company offers for the purchase of all or part of the Stock from the
Company in connection with the proposed offering of the Stock.

(b) The Company has filed a registration statement on Form S-3 (Registration
File No. 333-107799), which became effective as of August 25, 2003, for the
registration of the Stock under the Securities Act of 1933, as amended, (the
“Securities Act”). The Company will file with the United States Securities and
Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the
Securities Act, and the rules and regulations of the Commission promulgated
thereunder, a supplement to the form of prospectus included in such registration
statement relating to a placement of the Stock and the plan of distribution
thereof and has advised the Placement Agent of all further information
(financial and other) with respect to the Company to be set forth therein. Such
registration statement, including the exhibits thereto, as amended at the date
of this Agreement, as applicable, is hereinafter called the “Registration
Statement;”

 

--------------------------------------------------------------------------------

 

such prospectus in the form in which it appears in the Registration Statement is
hereinafter called the “Base Prospectus;” and the supplemented form of
prospectus, in the form in which it will be filed with the Commission pursuant
to Rule 424(b) (including the Base Prospectus as so supplemented) is hereinafter
called a “Prospectus Supplement.” The Placement Agent agrees, as agent of the
Company, to use its best efforts to solicit offers to purchase the Stock from
the Company on the terms and subject to the conditions set forth in the Base
Prospectus and the Registration Statement. The Placement Agent shall make
commercially reasonable efforts to assist the Company in obtaining performance
by each Investor whose offer to purchase Stock has been solicited by the
Placement Agent and accepted by the Company, but the Placement Agent shall not
have any liability to the Company in the event any such purchase is not
consummated for any reason.

(c) The Placement Agent represents and warrants to the Company that (i) it is a
duly registered, licensed and qualified corporate finance advisor pursuant to
the regulations and requirements of the Financial Services Authority (the “FSA”)
and any other applicable regulatory body governing the offer or sale of
securities in the United Kingdom, and is licensed and qualified as such in any
jurisdiction in which the Placement Agent offers, or has offered, any of the
Stock, (ii) its participation in the offering and sale of the Stock will be in
accordance with the provisions of the Securities Act, the regulations
promulgated pursuant thereto, all other regulations of the Commission, the rules
and regulations of the National Association of Securities Dealers in the United
States, the provisions of the Financial Services and Markets Act 2000, the
regulations issued thereunder (including without limitation the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2001), the Public
Offers of Securities Regulations 1995, and the applicable requirements
(including the relevant conduct of business rules) of the FSA and any other
applicable regulatory body governing the offer or sale of securities in the
United Kingdom, (iii) it has not distributed and will not distribute prior to
the closing date any offering material in connection with the offer and sale of
the Stock, or any other Company securities, other than the Registration
Statement and the Base Prospectus, and (iv) entry by the Company into the
Subscription Agreements will not result in the Company being in breach of the
provisions of the Financial Services and Markets Act 2000, the regulations
issued thereunder (including without limitation the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2001), the Public Offers of
Securities Regulations 1995, and the applicable requirements (including the
relevant conduct of business rules) of the FSA and any other applicable
regulatory body governing the offer or sale of securities in the United Kingdom.

(d) Subject to the provisions of this Section 1, offers for the purchase of
Stock may be solicited by the Placement Agent as agent for the Company at such
times and in such amounts as agreed by the Placement Agent and the Company. The
Placement Agent shall communicate to the Company, orally or in writing, each
reasonable offer to purchase Stock received by it as agent of the Company. The

2

--------------------------------------------------------------------------------

 

Company shall have the sole right to accept offers to purchase the Stock and may
reject any such offer, in whole or in part, in its sole discretion. The
Placement Agent shall have the right, in its discretion reasonably exercised,
without notice to the Company, to reject any offer to purchase Stock received by
it, in whole or in part, and any such rejection shall not be deemed a breach of
its agreement contained herein.

(e) The purchases of the Stock by the Investors shall be evidenced by the
execution of the Subscription Agreements.

(f) As compensation for services rendered, on the Closing Date (as defined
below) the Company shall pay to the Placement Agent by wire transfer of
immediately available funds to an account or accounts designated by the
Placement Agent, an aggregate amount equal to five percent (5.0%) of the gross
proceeds received by the Company from the sale of the Stock on such Closing
Date. In addition, if (i) the Closing Date is on or prior to December 15, 2004
and (ii) there has not been, as determined by the Company in its reasonable
discretion, any significant or suspicious trading activity in the Company’s
securities prior to the Closing Date indicating any market knowledge of the
placement or any other proposed transaction, the Company shall issue to
Placement Agent or its designee warrants to purchase a number of shares of the
Company’s common stock equal to one and one-fourth percent (1 1/4%) of the
aggregate gross proceeds received by the Company in one or more Closings, at a
per share purchase price equal to one hundred percent (100%) of the per share
purchase price of the Company’s shares issued at such Closing or Closings;
provided, however, that any such warrants shall be to purchase no fewer than
187,500 shares of the Company’s common stock if aggregate gross proceeds of at
least U.S. $15,000,000 are received by the Company at the Closing or Closings.
Further, if a Financing of US $20 million or more is attained, the minimum
number of share warrants will equal 275,000 and amounts in excess of US $20
million will earn share warrants at the increased rate of one and one-half
percent (1.5%) of the Financing amount.

(g) No Stock which the Company has agreed to sell pursuant to this Agreement
shall be deemed to have been purchased and paid for, or sold by the Company,
until such Stock shall have been delivered to the Investor thereof against valid
payment by such Investor.

2. THE CLOSING. The time and date of any closing (each a “Closing”) shall be at
9:00 A.M., local time, on or about December 8, 2004 (the “Closing Date”) at the
office of Wilson Sonsini Goodrich & Rosati, counsel for the Company, at 8911
Capital of Texas Highway North, Westech 360, Suite 3350, Austin, Texas, or
another time and place mutually agreed by the parties Subject to the terms and
conditions hereof, payment of the purchase price for the Stock shall be made in
United States dollars to the Company by United States Federal funds wire
transfer, against delivery of the certificates for the Stock, through the
facilities of The Depository Trust Company (“DTC”), to Investor or its designee,
and shall be registered in such name or names and shall be in such

3

--------------------------------------------------------------------------------

 

denominations, as the Investor may request no later than one business day
following its execution of a Subscription Agreement for shares of the Stock.

3. ADDITIONAL REPRESENTATIONS AND COVENANTS. The Placement Agent represents,
warrants and agrees that it has not (i) engaged in any short selling or short
sales “against the box” in the Company’s securities, (ii) established or
increased any “put equivalent position” as defined in Rule 16(a)-1(h) under the
Securities Exchange Act of 1934, as amended, with respect to the Company’s
securities, or (iii) engaged in any purchase or sale, or made any offer to
purchase or offer to sell, derivative securities relating to the Company’s
securities, whether or not issued by the Company, such as exchange traded
options to purchase or sell the Company’s securities (“puts” and “calls”),
within the past ninety (90) trading days. The Placement Agent further covenants
with the Company that, for a period of twelve (12) months following the date of
this Agreement, it shall not engage in any such activities set forth in clauses
(i) through (iii) above with respect to the Company’s securities.

4. SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement shall
inure to the benefit of and be binding upon the Placement Agent, the Investors,
the Company, and their respective successors. Nothing expressed or mentioned in
this Agreement is intended or shall be construed to give any person other than
the persons mentioned in the preceding sentence any legal or equitable right,
remedy or claim under or in respect of this Agreement, or any provisions herein
contained, this Agreement and all conditions and provisions hereof being
intended to be and being for the sole and exclusive benefit of such persons and
for the benefit of no other person

5. SURVIVAL. Notwithstanding any investigation made by any party to this
agreement, the provisions of this Agreement shall survive the execution of this
Agreement, the delivery to the Investor of the Stock being purchased and the
payment therefor.

6. NOTICES. All statements, requests, notices and agreements hereunder shall be
in writing, and:

(a) if to the Placement Agent, shall be delivered or sent by mail, telex or
facsimile transmission to:

     

  Mulier Capital Limited

  34 Eccleston Square

  London SW1V1NS

  London, United Kingdom

  Fax: 020 7821 5999

(b) if to the Company, shall be delivered or sent by mail, telex or facsimile
transmission to:

4

--------------------------------------------------------------------------------

 

     

  Introgen Therapeutics, Inc.

  301 Congress Avenue, Suite 1850

  Austin, Texas 78701

  Attention: Chief Executive Officer

  Phone: (512) 708-9310

  Fax: (512) 708-9311
 
   

  with copies to:
 
   

  Wilson Sonsini Goodrich & Rosati, P.C.

  8911 Capital of Texas Highway

  Westech 360, Suite 3350

  Austin, Texas 78759-8497

  Attention: Christopher J. Ozburn

  Phone: (512) 338-5400

  Fax: (512) 338-5499
 
   

  and:
 
   

  Wilson & Varner, LLP

  301 Congress Avenue, Suite 2025

  Austin, Texas 78701

  Attention: Rodney Varner

  Phone: (512) 320-4160

  Fax: (512) 495-9441

7. PARTIAL UNENFORCEABILITY. The invalidity or unenforceability of any Section,
paragraph or provision of this Agreement shall not affect the validity or
enforceability of any other Section, paragraph or provision hereof. If any
Section, paragraph or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor
changes (and only such minor changes) as are necessary to make it valid and
enforceable.

8. GENERAL. This Agreement and the Confidential Disclosure Agreement between the
parties effective October 26, 2004 constitute the entire agreement of the
parties to this Agreement and supersede all prior written or oral and all
contemporaneous oral agreements, understandings and negotiations with respect to
the subject matter hereof. The headings of the various sections of this
Agreement have been inserted for convenience of reference only and will not be
deemed to be part of this Agreement. This Agreement may not be modified or
amended except pursuant to an instrument in writing signed by the Company and
the Placement Agent.

9. COUNTERPARTS. This Agreement may be executed in two or more counterparts,
each of which will constitute an original, but all of which, when taken
together, will constitute but one instrument, and will become effective when one
or more counterparts have been signed by each party hereto and delivered to the
other parties.

5

--------------------------------------------------------------------------------

 

     If the foregoing is in accordance with your understanding of the agreement
between the Company and the Placement Agent, kindly indicate your acceptance in
the space provided for that purpose below.

              Very truly yours,
 
            INTROGEN THERAPEUTICS, INC.
 
       

  By:   /s/ James W. Albrecht, Jr.

     

--------------------------------------------------------------------------------

      Name: James W. Albrecht, Jr.

      Title:   Chief Financial Officer

Accepted as of
the date first above written:

MULIER CAPITAL LIMITED

     
By:
  /s/ Pieter Mulier

 

--------------------------------------------------------------------------------

  Name:  Pieter Mulier

  Title:    CEO

6

--------------------------------------------------------------------------------

 

Exhibit A

Form of Subscription Agreement